A950220 Stock Overview
NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NeoImmuneTech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,410.00 |
| 52 Week High | ₩3,305.00 |
| 52 Week Low | ₩1,180.00 |
| Beta | 0.90 |
| 1 Month Change | -8.86% |
| 3 Month Change | -18.73% |
| 1 Year Change | -56.62% |
| 3 Year Change | -89.15% |
| 5 Year Change | n/a |
| Change since IPO | -90.17% |
Recent News & Updates
Shareholder Returns
| A950220 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -6.3% | -0.6% | -2.4% |
| 1Y | -56.6% | 2.4% | 1.9% |
Return vs Industry: A950220 underperformed the KR Biotechs industry which returned 2.4% over the past year.
Return vs Market: A950220 underperformed the KR Market which returned 1.9% over the past year.
Price Volatility
| A950220 volatility | |
|---|---|
| A950220 Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A950220's share price has been volatile over the past 3 months.
Volatility Over Time: A950220's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 100 | Luke Yun Oh | www.neoimmunetech.com |
NeoImmuneTech, Inc., a clinical-stage T cell-focused biotech company, develops and sells immuno-therapeutics. It is developing NT-I7, a clinical-stage long-acting human IL-7 for oncologic and infectious diseases. The company was incorporated in 2014 and is headquartered in Rockville, Maryland.
NeoImmuneTech, Inc. Fundamentals Summary
| A950220 fundamental statistics | |
|---|---|
| Market cap | ₩27.88b |
| Earnings (TTM) | -₩53.40b |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs A950220 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A950220 income statement (TTM) | |
|---|---|
| Revenue | ₩0 |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩0 |
| Other Expenses | ₩53.40b |
| Earnings | -₩53.40b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.70k |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did A950220 perform over the long term?
See historical performance and comparison